БИБЛИОГРАФИЯ. 1. Report on the Global HIV/AIDS epidemic

1. Report on the Global HIV/AIDS epidemic. Geneva, Joint United Nations Programme on HIV/AIDS, 1997: 1-13.

2. AIDS epidemic update: December 1998. Geneva, Joint United Nations Programme on HIV/AIDS, 1998.

3. Gregson S, Garnett GP, Anderson RM. Is HIV-1 likely to become a leading cause of adult mortality in subSaharan Africa? J Acquir Immune Defic Syndr, 1994, 7(8): 839-852.

4. World AIDS day 1996. One world one hope. Geneva, Joint United Nations Programme on HIV/AIDS, 1996.

5. Minkoff H. Pregnancy and HIV infection. In: HIV infection in women, Minkoff H, DeHovitzJA, Duerr A (eds). New York, Raven Press, 1995: 173-188.

6. Miyazaki M. Epidemiological characteristics of human immunodeficiency virus type-2 infection in Africa. Int J STD AIDS, 1995, 6(2): 75-80.

7. Kanki P et al. HIV-2 provides natural protection against HIV-1 infection. IX International conference on AIDS and STD in Africa, Kampala, 1995, Abstract MoA026.

8. Gnaore E et al. Prevalence and mortality from HIV Type 2 in Guinea Bissau, West Africa. Lancet, 1989, 334 (ii): 513.

9. Matheron S et al. Vertical transmission of HIV-2. Lancet, 1990, 335: 1103-1104.

10. HIV/AIDS: the global epidemic. Geneva, Joint United Nations Programme on HIV/AIDS, 1996 (fact sheet).

11. Fowler MG, Melnick SL, Mathieson BJ. Women and HIV. Epidemiology and global overview. Obstet Gynecol Clin North Am, 1997, 24(4): 705-729.

12. Gregson S et al. Recent upturn in mortality in rural Zimbabwe: evidence for an early demographic effect of HIV-1 infection. AIDS, 1997, 11(10): 1269-1280.

13. Selik R, Chu S. HIV infection as a leading cause of death among young adults in US cities and states. JAMA, 1991, 271: 903.

14. Rogers MF. Epidemiology of HIV/AIDS in women and children in the USA. Acta Pediatr, 1997, Suppl 421: 15-16.

15. Brotman R et al. Childbearing women at risk for HIV infection in New York City. AIDS & Public Policy J, 1993, 8(4): 186-193.

16. European Collaborative Study. Characteristics of pregnant HIV-1 infected women in Europe. AIDS Care, 1996, 8(1): 33-42.

17. Newell ML, Thorne C. Pregnancy and HIV infection in Europe. Acta Pediatr, 1997, Suppl 421: 10-14.

18. Centers for Disease Control and Prevention. AIDS among children - United States 1996. MMWR, 1996, 45: 1005-1010.

19. Department of Health, South Africa. Sixth National HIV survey of women attending antenatal clinics of the public health services in the Republic of South Africa, October/November 1995. Epidemiological Comments, 1996, 23(1): 3-17.

20. Namibia updates its figures - what more should it do as a response? AIDS Analysis Africa, 1997, 7(3): 1.

21. Taha TE et al. Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS, 1998, 12(2): 197-203.

22. Boisson E et al. Interpreting HIV seroprevalence data from pregnant women. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 13: 434-439.

23. Dondero TJ, Gill ON. Large scale HIV serologic surveys: what has been learned? AIDS, 1991, 5(Suppl 1): S63-S69.

24. Borgdorff M et al. Sentinel surveillance for HIV-1 infection: how representative are blood donors, outpatients with fever, anaemia or sexually transmitted diseases, and antenatal clinic attenders in Mwanza Region, Tanzania. AIDS, 1993, 7: 567-572.

25. Gray RH et al. Population-based study of fertility in women with HIV-1 infection in Uganda. Lancet, 1998, 351: 98-103.

26. Asiimwe-Okiror G et al. Change in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda. AIDS, 1997, 11(14): 1757-1763.

27. Downs AM, De Vincenzi I, for the European Study Group in Heterosexual Transmission of HIV. Probability of heterosexual transmission of HIV: relationship to number of unprotected sexual contacts. J Acquir Immune Defic Syndr, 1996, 11: 388-395.

28. Royce RA et al. Sexual transmission of HIV. N Engl J Med, 1997, 15: 1072-1078.

29. Soto-Ramirez LE et al. HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science, 1996, 271: 1291-1293.

30. Klouman E et al. HIV and reproductive tract infections in a total village population in rural Kilimanjaro, Tanzania: women at increased risk. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14: 163-168.

31. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseases and HIV infection: implications for the control of both epidemics in Africa. AIDS, 1991, 5(Suppl 1): 55-63.

32. Ghys PD et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS, 1997, 11(12): F85-F93.

33. Dallabetta G. HIV and STDs: how are they linked? Africa Health, 1994, November: 19-20.

34. Hoegsberg B et al. Sexually transmitted diseases and human immunodeficiency virus among women with pelvic inflammatory disease. Am J Obstet Gynecol, 1990, 163: 1135-1139.

35. Irwin L, Ellerbrock T. Does pelvic inflammatory disease increase the risk for acquisition of human immunodeficiency virus type 1? (letter). J Infect Dis, 1995, 172: 898-899.

36. Mayaud P. Tackling bacterial vaginosis and HIV in developing countries. Lancet, 1997, 350: 530-531.

37. Sewankambo N et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet, 1997, 350: 546-550.

38. Laga M et al. Nonulcerative sexually transmitted diseases on HIV as risk factors for HIV‑ 1 transmission in women: results from a cohort study. AIDS, 1993, 7: 95-102.

39. Mlisana KP et al. Syphilis in the “unbooked” pregnant woman. S Afr Med J, 1992, 82: 18-20.

40. Qolohle DC et al. Serological screening for sexually transmitted infections in pregnancy: is there any value in re-screening for HIV and syphilis at the time of delivery. Genitourin Med, 1995, 71: 65-67.

41. Mosha F et al. A population based study of syphilis and sexually transmitted disease syndromes in northwestern Tanzania. I. Prevalence and incidence. Genitourin Med, 1993, 69: 415-420.

42. Latif AS et al. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS, 1989, 3: 519-523.

43. Johnson MA et al. Transmission of HIV to sexual partners of infected men and women. AIDS, 1989, 3: 367-372.

44. Plourde PJ et al. Human immunodeficiency virus type-1 seroconversion in women with genital ulcers. J Infect Dis, 1994, 170: 313-317.

45. Mbizvo M et al. Trends in HIV-1 and HIV-2 prevalence and risk factors in pregnant women in Harare, Zimbabwe. Cent Afr J Med, 1996, 42(1): 14-21.

46. Grosskurth H et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in northern Tanzania: randomised controlled trial. Lancet, 1995, 346: 530-536.

47. Feldmeier H, Krantz I, Poggensee G. Female genital schistosomiasis as a risk factor for the transmission of HIV. Int J STD AIDS, 1994, 5(5): 368-372.

48. Plummer FA et al. Co-factors in male-female sexual transmission of human immunodeficiency virus type -1. J Infect Dis, 1991, 163: 233-239.

49. Daly CC et al. Contraceptive methods and the transmission of HIV: implications for family planning. Genitourin Med, 1994, 70(2): 110-117.

50. Lamptey P, Potts M. Targeting of prevention programs in Africa. In: Lamptey P, Piot P (eds). AIDS Prevention Handbook. Durham, Family Health International, 1990.

51. Campbell T, Kelly M. Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. AIDS Care, 1995, 7(3): 365-373.

52. Runyanga A. Pitts M, McMaster J. The use of herbal and other agents to enhance sexual experience. Soc Sci Med, 1992, 35(8): 1037-1042.

53. Runyanga A, Kasule J. The vaginal use of herbs/substances: an HIV transmission factor? AIDS Care, 1995, 7(5): 639-645.

54. Civic D, Wilson D. Dry sex in Zimbabwe and implications for condom use. Soc Sci Med, 1996, 42: 91-98.

55. Gresenguet G et al. HIV infection and vaginal douching in Central Africa. AIDS, 1997, 11: 101-106.

56. Dallabetta GA et al. Traditional vaginal agents: use and association with HIV infection in Malawian women. AIDS, 1995, 9: 193-297.

57. Sandala L et al. " Dry Sex" and HIV infection among women attending a sexually transmitted diseases clinic in Lusaka, Zambia. AIDS, 1995, 9(Suppl 1): S61-S68.

58. Taha TE et al. Knowledge of HIV status and its influence on Reproductive intentions of women in Blantyre, Malawi. Xth International Conference on AIDS and STD in Africa, Abidjan, Cô te d’Ivoire, 7-11 December 1997, Abstract.

59. Ahluwalia IB, De Villis RF, Thomas JC. Reproductive decisions of women at risk for acquiring HIV infection. AIDS Educ Prev, 1998, 10(1): 90-97.

60. Feldblum PJ et al. The effectiveness of barrier methods in preventing the spread of HIV. AIDS, 1995, 9(Suppl A): 585-593.

61. Drew WL et al. Evaluation of the virus permeability of a new condom for women. Sexually Transmitted Diseases, 1990, 17: 110-112.

62. Lindgren S et al. A Pattern of HIV viraemia and CD4 levels in relation to pregnancy in HIV 1 infected women. Scan J Infect Dis, 1996, 28: 425-433.

63. Rich KC et al. CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis, 1995, 172: 1221-1227.

64. Jensen LP et al. Acquired immune deficiency syndrome in pregnancy. Am J Obstet Gynecol, 1984, 148(8): 1145-6.

65. Minkoff H et al. Pregnancies resulting in infants with acquired immune deficiency syndrome or AIDS related complex. Obstet Gynecol, 1987, 69: 285.

66. Hocke C et al and the Groupe d'é pidé miologie clinique du SIDA en Aquitaine. Prospective cohort study of the effect of pregnancy in the progression of human immunodeficiency virus infection. Obstet Gynecol, 1995, 86(6): 886-891.

67. Brettle RP et al. HIV infection in women: immunological markers and the influence of pregnancy. AIDS, 1995, 9: 1177-1184.

68. Weisser M et al. The Swiss HIV Cohort Study (SHCS), and the Swiss Collaborative HIV and Pregnancy Study (SCHPS). Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies. J Acquir Immune Defic Syndr Hum Retrovirol, 1998, 17(5): 404‑ 410.

69. Schaefer A et al. The effect of pregnancy on the natural course of HIV infection. IV International Conference on AIDS, Stockholm, 1988, Abstract 4039.

70. Bessinger R et al. Pregnancy is not associated with the progression of HIV disease in women attending an HIV outpatient program. Am J Epidemiol, 1998 147(5): 434-440.

71. Landers DV, Martinez de Tejada B, Coyne BA. Immunology of HIV and pregnancy. The effects of each on the other. Obstet Gynecol Clin North Am, 1997, 24(4): 821-831.

72. Biggar RJ et al. Helper and suppresser lymphocyte changes in HIV-infected mothers and their infants. IV International Conference on AIDS, Stockholm, 1988, Abstract 4032.

73. French R, Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of literature and meta‑ analysis. Br J Obstet Gynaecol, 1998, 105: 827‑ 835.

74. Burns DN et al. The influence of pregnancy on human immunodeficiency virus type 1 infection: antepartum and postpartum changes in human immunodeficiency virus type 1 viral load. Am J Obstet Gynecol, 1998, 178(2): 355-359.

75. Temmerman M. Human immunodeficiency virus and women. J Obstet Gynecol, 1994, 14(Suppl 2): S70-S75.

76. Ryder RW, Temmerman M. The effects of HIV-1 infection during pregnancy and the perinatal period on maternal and child health in Africa. AIDS, 1991, 5(Suppl 1): S75-S85.

77. Johnstone FD. Pregnancy outcome and pregnancy management in HIV-infected women. In: Johnson MA, Johnstone FD (eds). HIV Infection in women. Edinburgh, Churchill Livingstone, 1993: 187-198.

78. Temmerman M et al. HIV-1 and immunological changes during pregnancy: a comparison between HIV-1 seropositive and HIV-1 seronegative women in Nairobi, Kenya. AIDS, 1995, 9: 1057-1060.

79. Miotti PG, Chiphangwi JD, Dallabetta G. The situation in Africa. Ballieres Clinical Obstet Gynecol, 1992, 6(1): 165-185.

80. Taha TET et al. HIV, maternal death and child survival in Africa. AIDS, 1996, 10(1): 111-112.

81. Ryder RW et al. Mortality in HIV-1 seropositive women, their spouse and their newly born children during 36 months of follow up in Kinshasa, Zaire. AIDS, 1994, 8: 667-672.

82. Bakas C, Zarou DM, de Caprariis PJ. First-trimester spontaneous abortions and the incidence of human immunodeficiency virus seropositivity. J Reprod Med, 1996, 41(1): 15-18.

83. Johnstone FD. HIV and pregnancy. Br J Obstet Gynaecol, 1996, 103: 1184-1190.

84. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta‑ analysis. British Journal of Obstetrics and Gynaecology, 1998, 105: 839‑ 848.

85. Turner BJ et al. Prenatal care and birth outcomes of a cohort of HIV-infected women. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 12: 259-267.

86. Turner NJ et al. Prenatal care of HIV-infected women: analysis of a large New York State cohort. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 9: 371-378.

87. Hira SK et al. Apparent vertical transmission of HIV-1 by breastfeeding in Zambia. J Paediatr, 1990, 117: 421-424.

88. McIntyre JA. Pregnancy and HIV infection at Baragwanath Hospital, 1987-1993. Eighth International Conference on AIDS and STD in Africa, Marrakesh, 1993, Abstract ThOP13.

89. Ryder RW et al. Perinatal transmission of the human immunodeficiency virus type-1 to infants of seropositive women in Zaire. N Engl J Med, 1989, 320: 1637-1642.

90. Temmerman M et al. Infection with HIV as a risk factor for adverse pregnancy outcome. AIDS, 1990, 4: 139-144.

91. Minkoff HL et al. Serious infections during pregnancy among women with advanced human immunodeficiency virus infection. Am J Obstet Gynecol, 1990, 162: 30-34.

92. Langston C et al. Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection. J Infect Dis, 1995, 172: 1451-1460.

93. D'Ubaldo C et al. Association between HIV-1 infection and miscarriage: a retrospective study. AIDS, 1998, 12(9): 1087-93.

94. Byabamazina CR et al. HIV/Syphilis serology as an indicator of past pregnancy outcomes among antenatal attendees in Kampala. IXth International Conference on AIDS and STD in Africa, Kampala, 1995, Abstract TuC108.

95. Shearer WT et al. Early spontaneous abortion and fetal thymic abnormalities in maternal-to-fetal HIV infection. Acta Pediatr, 1997, Suppl 421: 60-64.

96. Klugman KP et al. Serological markers of sexually transmitted diseases associated with HIV-1 infection in pregnant black women. S Afr Med J, 1991, 80: 243-244.

97. Leroy V et al. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? Genitourin Med, 1995, 71(4): 207-211.

98. Johnstone FD et al. Does infection with HIV affect the outcome of pregnancy? Br Med J, 1988, 296: 487.

99. Mauri A et al. Obstetric and perinatal outcome in human immunodeficiency virus-infected pregnant women with and without opiate addiction. Euro J Obstet Gynecol, 1995, 58: 135-140.

100. Taha TET et al. The effect of human immunodeficiency virus infection on birthweight, and infant and child survival in urban Malawi. Int J epidemiol, 1995, 24: 1022-1028.

101. Rabkin CS et al. Kaposi's sarcoma in pregnant women. Nature, 1995, 377: 21-22.

102. Bergstrom S et al. HIV infection and maternal outcome of pregnancy in Mozambican women: a case control study. Genitourin Med, 1995, 71: 323-324.

103. Braddick MR et al. Impact of maternal HIV infection on obstetrical and early pregnancy outcome. AIDS, 1990, 4: 1001-1005.

104. Spinello A et al. The effect of fetal infection with human immunodeficiency virus type 1 on birthweight and length of gestation. Euro J Obstet Gynecol, 1994, 57: 13-17.

105. Markson LE et al. Association of maternal HIV infection with low birth weight. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 13(3): 227-234.

106. Johnstone FD, Raab GM, Hamilton BA. The effect of human immunodeficiency virus infection and drug use on birth characteristics. Obstet Gynecol, 1996, 88(3): 321-326.

107. Leroy V et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. AIDS, 1998, 12(6): 643-650.

108. Gray G, McIntyre JA, Pettifor J. Difference in growth and illness between breastfed and formula fed infants born to HIV positive women in Soweto. IXth International Conference on AIDS and STD in Africa, Kampala, 1995, Abstract ThB280.

109. Bulterys M et al. Fatal complications after Caesarian section in HIV-infected women. AIDS, 1996, 10(8): 923-924.

110. Semprini AE et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS, 1995, 9: 913-917.

111. Newell M-L, Gray G, Bryson YJ. Prevention of mother-to child transmission of HIV-1 transmission. AIDS, 1997, 11(Suppl A): S165-S172.

112. Working Group on mother-to-child transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 8: 506-510.

113. Reggy A, Simonds RJ, Rogers M. Preventing perinatal HIV transmission. AIDS, 1997, 11(Suppl A): S61-S67.

114. Simonds RJ et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. Perinatal AIDS Collaborative Transmission Studies. AIDS, 1998, 12(3): 301-308.

115. Backe E et al. Fetal organs infected by HIV-1. AIDS, 1993, 7: 896-897.

116. Mofenson LM. Interaction between the timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Pediatr, 1997, Suppl 421: 1-9.

117. Viscarello RR et al. Fetal blood sampling in HIV- seropositive women before elective midtrimester termination of pregnancy. Am J Obstet Gynecol, 1992, 167: 1075-1079.

118. Goedert JJ et al. International Registry of HIV-exposed twins. High risk of HIV-1 infection for first born twins. Lancet, 1991, 338: 1471-1475.

119. European Collaborative Study. Caesarean section and the risk of vertical transmission of HIV-1 infection. Lancet, 1994, 343: 1464-1467.

120. Landesman SH et al for the Women and Infants Transmission Study. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med, 1996, 334: 1617-1623.

121. Brossard Y et al. Frequency of early in-utero HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. AIDS, 1995, 9(4): 359-366.

122. Mofenson LM. Mother-child HIV-1 transmission: timing and determinants. Obstetr Gynecol Clin North Am, 1997, 24(4): 759-784.

123. Fowler MG. Update: transmission of HIV-1 from mother to child. Curr Opin Obstet Gynecol, 1997, 9(6): 343-348.

124. Kuhn L et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS, 1997, 11: 429-435.

125. Choquet C et al. Timing of mother-to-child transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric methods. AIDS, 1997, 11: 1183-1199.

126. Vials JM. A review of the literature on prevention of early vertical transmission of the HIV virus. Midwifery, 1997, 13(4): 216-220.

127. Bryson YJ et al. Proposed definition for in-utero versus intrapartum transmission of HIV-1. N Engl J Med, 1992, 327: 1246-1247.

128. Rouzioux C et al and the HIV infection in newborns French Collaborative Study Group. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Marcov model. Am J Epidemiol, 1995, 142(12): 1330-1337.

129. Kalish LA et al. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 on the basis of age at first positive culture. J Infect Dis, 1997, 175: 712-715.

130. Bertolli J et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breastfeeding cohort in Kinshasa, Zaire. J Infect Dis, 1996, 174: 722-726.

131. Bryson Y. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS, 1996, 10(Suppl 3): S33-S42.

132. Steihm ER. Newborn factors in maternal-infant transmission of pediatric HIV infection. J Nutr, 1996, 126: 2632S-2636S.

133. Goedert JJ et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti gp-120. Lancet, 1989, 2: 1351-1354.

134. Shearer WT, Kalish LA, Zimmerman PA. CCR5 HIV-1 vertical transmission. Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr Hum Retrovirol, 1998, 17(2): 180-181.

135. Mtimavalye L et al. Maternal-infant transmission of HIV-1. N Engl J Med, 1995, 332: 890-891.

136. Ryder RW, Behets F. Reasons for the wide variation in reported rates of mother-to-child transmission of HIV-1. AIDS, 1994, 8: 1495-1497.

137. Nieburg P et al. Contribution of breastfeeding to the reported variation in rates of mother-to-child HIV transmission. AIDS, 1995, 9(4): 396-397.

138. Hengel RL et al. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS Res Hum Retroviruses, 1998, 14(6): 475-481.

139. Cohen M et al. Prophylactic cesarean section and HIV seropositive patients. J Gynecol Obstet Biol Reprod, 1996, 25(8): 846-850.

140. Newell ML. Mechanisms and timing of mother-to-child transmission of HIV‑ 1. AIDS, 1997, 12: 831-837.

141. Butlerys M, Lepage P. Mother-to-child transmission of HIV. Curr Opin Ped, 1998, 10: 143-150.

142. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet, 1992, 339: 1007-1012.

143. Mayaux MJ et al. Maternal factors associated with perinatal HIV-1 transmission: the French cohort study: 7 years of follow up observation. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 8: 188-194.

144. Mayaux MJ et al. Maternal viral load during pregnancy and mother-to child transmission of human immunodeficiency virus type 1: the French Perinatal Cohort Studies. J Infect Dis, 1997, 175: 172-175.

145. Thea DM et al and the New York City Perinatal HIV Transmission Collaborative Group. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS, 1997, 11: 437-444.

146. Sperling R et al. Maternal plasma HIV-1 RNA and the success of zidovudine (ZDV) in the prevention of mother-to-child transmission. Third International Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996, Abstract LB1.

147. Burchett S et al. Assessment of maternal plasma viral load as a correlate of vertical transmission. Third International Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996, Abstract LB3.

148. Coll O et al. Vertical HIV-1 transmission correlated with a high maternal viral load at delivery. J Acquir Immune Defic Hum Retrovirol, 1997, 14: 26-30.

149. Scarlatti G et al. Transmission of human immunodeficiency virus type 1 (HIV‑ 1) from mother to child correlates with viral phenotype. Virology, 1993, 197: 624-629.

150. Thea DM et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. J Infect Dis, 1997 175: 707-711.

151. Cao Y et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nature Medicine, 1997, 3: 549-552.

152. O'Shea S et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol, 1998, 54(2): 113-117.

153. Shaffer N et al. High maternal viral load predicts perinatal HIV-1 transmission and early infant progression. Third International Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996, Abstract 30.

154. Fang G et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA, 1995, 92: 12100-12104.

155. Koup R et al. Lack of maternal viral threshold for vertical transmission of HIV-1. Third International Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996, Abstract LB2.

156. John GC, Kreiss J. Mother-to child transmission of human immunodeficiency virus type 1. Epidemiol Rev, 1996, 18(2): 149-157.

157. Clemetson DBA et al. Detection of HIV DNA in cervical and vaginal secretions. JAMA, 1993, 269: 2860-2864.

158. Loussert-Ajaka I et al. HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS, 1997, 11(13): 1575-1581.

159. Nduati R et al. Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis, 1995, 172: 1461-1468.

160. John GC et al. Genital shedding of human immunodeficiency virus type-1 DNA during pregnancy: association with immunosuppression, abnormal cervical and vaginal discharge and severe vitamin A deficiency. J Infect Dis, 1997, 175(1): 57-62.

161. Van de Perre P et al. Infective and anti-infective properties of breast milk from HIV-1 infected women. Lancet, 1993, 341(8850): 914-8.

162. Landers DV. Nutrition and immune function II: maternal factors influencing transmission. J Nutr, 1996, 126: S2637-2640.

163. Dickover RE et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA, 1996, 275: 599-605.

164. Bulterys M, Lepage P. Mother-to-child transmission of HIV. Curr Opin Pediatr, 1998, 10(2): 143-150.

165. Boswell et al. The distribution of HIV-1 serotypes in Africa. IX International Conference on AIDS and STD in Africa, Kampala, 1995, Abstract MoA041.

166. Kunanusont C et al. HIV-1 subtypes and male to female transmission in Thailand. Lancet, 1995, 345: 1078-1083.

167. Cavaco-Silva P et al. Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. J Virol, 1998, 72(4): 3418-3422.

168. Lamers SL et al. Persistence of multiple maternal genotypes of human immunodeficiency virus type 1 in infants infected by vertical transmission. J Clin Invest, 1994, 93: 380-390.

169. Wolinsky SM et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to children. Science, 1992, 225: 1134-1137.

170. Scarlatti G et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA, 1993, 90: 1721-1725.

171. Ometto L et al. Viral phenotype and host cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS, 1996, 9: 427-434.

172. Spencer TL, Danker OM, Spector SA. Clinical significance of HIV-1 phenotype in infected children. J Infect Dis, 1994, 169: 491-495.

173. Reinhardt PP et al. Human cord blood mononuclear cells are preferentially infected by non syncitium-inducing, macrophage-tropic human immunodeficiency type 1 isolates. J Clin Microbiol, 1995, 33: 292-297.

174. van't Wout AB et al. Macrophage-tropic variants initiate human immunodeficiency virus type-1 infection after sexual, parenteral, and vertical transmission. J Clin Invest, 1994, 94(5): 2060-2067.

175. Colognesi C et al. The role of virologic and immunologic factors in mother-to-child transmission of HIV-1. Am J Reprod Immunol, 1997, 38(3): 197-200.

176. De Rossi A et al. Viral phenotype in mother-to-child HIV-1 transmission and disease progression of vertically acquired HIV-1 infection. Acta Pediatr, 1997 Suppl 421: 22-28.

177. Bulterys M, Goedert JJ. From biology to sexual behaviour - towards the prevention of mother to child transmission of HIV. AIDS, 1995, 10: 1287-1289.

178. Eastman PS et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis, 1998, 177(3): 557-564.

179. McIntosh K. Antiretroviral resistance and HIV vertical transmission. Acta Pediatr, 1997, Suppl 421: 29-32.

180. Fowler MG, Rogers MF. Overview of perinatal infection. J Nutr, 1996, 126: 2602S-2607S.

181. European Collaborative Study. Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS, 1996, 10: 1675-1681.

182. Pitt J et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis, 1997, 175: 567-575.

183. Lallemant M, Lallemant-Le Coeur S, Nzingoula S. Perinatal transmission of HIV in Africa. In: Essex M et al (eds). AIDS in Africa. New York, Raven Press, 1994: 211-235.

184. Wood L. Perinatal Transmission of HIV-1 (letter). JAMA, 1996, 276(16): 1300.

185. Scarlatti G et al. Mother to child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis, 1993, 168: 207-210.

186. Kliks SC et al. Features of HIV-1 that could influence maternal-child transmission. JAMA, 1994, 272: 467-474.

187. Husson RN et al. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load and virus phenotype. J Pediatr, 1995, 126: 865-871.

188. Bryson YJ et al. The role of maternal autologous neutralizing antibody in prevention of maternal fetal HIV-1 transmission. J Cell Biochem, 1993, Suppl 17E: 95.

189. Halsey NA et al. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant transmission. J Acquir Immune Defic Syndr, 1992, 5: 153-157.

190. Robertson CA et al. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus. J Infect Dis, 1992, 166: 704-709.

191. Jenkins M et al. Association between anti-human immunodeficiency virus type-1 (HIV-1) antibody-dependent cellular cytotoxicity antibody titres at birth and vertical transmission of HIV-1. J Infect Dis, 1994, 170: 308-312.

192. Ugen KE et al. Vertical transmission of Human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. J Infect Dis, 1997, 175: 63-69.

193. Van de Perre P et al. Postnatal transmission of HIV-1 associated with breast abscess. Lancet, 1992, 339: 1490-1491.

194. Nduati RW et al. Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis, 1995, 172(6): 1461-1468.

195. Semba RD et al. Maternal vitamin A deficiency and mother to child transmission of HIV‑ 1. Lancet, 1994, 343: 1593-1597.

196. Burger H et al. Maternal serum vitamin A levels are not associated with mother-to-child transmission in the United States. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14(4): 321-326.

197. Greenberg BL et al. Vitamin A deficiency and maternal-infant transmission of HIV in two metropolitan areas in the United States. AIDS, 1997, 11: 325-332.

198. Semba RD. Vitamin A, immunity and infection. Clin Infect Dis, 1994, 19: 489-499.

199. Burns DN et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr, 1994, 7: 718-726.

200. Turner BJ et al. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14: 327-337.

201. Matheson PB et al and the New York City Perinatal HIV transmission Collaborative Study. Association of maternal drug use during pregnancy with mother-to-child transmission. AIDS, 1997, 11(7): 941-942.

202. Rodriguez EM et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal transmission. AIDS, 1996, 10(3): 273-282.

203. Matheson PB et al. Heterosexual behaviour during pregnancy and perinatal transmission of HIV-1. AIDS, 1996, 10: 1249-1256.

204. Lallemant M et al. Mother to child transmission of HIV-1 in Congo, central Africa. AIDS, 1994, 8(10): 1451-1456.

205. Bulterys M et al. Multiple sexual partners and mother-to-child transmission of HIV-1. AIDS, 1993, 7: 1639-1645.

206. Naeye RL, Ross S. Coitus and chorioamnionitis: a prospective study. Hum Devel, 1983, 6: 91-94.

207. Mandelbrot L et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol, 1996, 175: 661-667.

208. Temmerman M et al. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol, 1995, 172: 700-705.

209. Wabire-Mangen F et al. Placental risk factors for the vertical transmission of HIV-1 in Uganda. XI International Conference on AIDS, Vancouver, 1996, Abstract TuC341.

210. Shearer WT et al. Role of placental cytokines and inflammation in vertical transmission of HIV infection. Acta Pediatr, 1997, Suppl 421: 33-38.

211. Anderson VM. The placental barrier to maternal HIV infection. Obstet Gynecol Clin North Am, 1997, 24(4): 797-820.

212. Douglas GC, King BF. Maternal-fetal transmission of human immunodeficiency virus: a review of possible routes and cellular mechanisms of infection. Clin Infect Dis, 1992, 15: 678-691.

213. St Louis ME et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic and placental factors. JAMA, 1993, 169: 2853-2859.

214. Boyer PJ et al. Factors predictive of maternal-fetal transmission of HIV-1. JAMA, 1994, 217: 1925-1930.

215. Burton GJ et al. Physical breaks in the placental trophoblastic surface: significance in vertical transmission of HIV. AIDS, 1996, 10(11): 1294-1295.

216. Bloland PB et al. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS, 1995, 9: 721-726.

217. Nahlen B et al. Association between placental malarial infection and increased risk of mother to infant transmission of HIV-1 in western Kenya. 12th World AIDS Conference, Geneva, 28 June - 3 July 1998, Abstract 23268.

218. Henin Y et al. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr, 1993, 6: 72-75.

219. Duliege AM et al. Birth order, delivery route and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. J Pediatr, 1995, 126: 625-632.

220. Datta P et al. Mother-to child transmission of Human Immunodeficiency Virus Type 1: Report from the Nairobi study. J Infect Dis, 1994, 170: 1134-1140.

221. Minkoff H et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol, 1995, 173: 585-589.

222. Biggar RJ et al. Perinatal intervention trial in Africa: effect of birth canal cleansing intervention to prevent HIV transmission. Lancet, 1996, 347: 1647-1650.

223. Kuhn L et al. Cesarean deliveries and maternal-infant HIV transmission: results from a prospective study in South Africa. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 11: 478-483.

224. [1]. Dunn DT et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. J Acquir Immune Defic Syndr, 1994, 7: 1064-1066.

225. Peckham C. Human immunodeficiency virus and mode of delivery. Acta Pediatr, 1997, Suppl 421: 104-106.

226. [1]. The European Mode of Delivery Collaboration. Elective caesarean‑ section versus vaginal delivery in prevention of vertical HIV‑ 1 transmission: a randomised clinical trial. Lancet, 1999, 353: 1035‑ 1039.

227. Kind C et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS, 1998, 12(2): 205-210.

228. Mandelbrot L et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA, 1 July 1998, 280(1): 55-60.

229. Luscher MA et al. Anti-HLA alloantibody is found in children but does not correlate with a lack of HIV type 1 transmission from infected mothers. AIDS Res Hum Retroviruses, 1998, 4(2): 99-107.

230. Misrahi M et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA, 1998, 279(4): 277-280.

231. Mangano A et al. Distribution of the CCR-5 delta32 allele in Argentinian children at risk of HIV-1 infection: its role on vertical transmission. AIDS, 1998, 12(1): 109-110.

232. MacDonald KS et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis, 1998, 177(3): 551-556.

233. Tovo P et al. Mode of delivery and gestational age influence perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol, 1996, 343: 390-391.

234. Mofenson L, Wolinsky SM. Current insights regarding vertical transmission. In: Pizzo PA, Wilfert CM (eds.) Paediatric AIDS, Edition 4. Baltimore, Williams and Wilkins, 1995: 179-203.

235. Goedert JJ. Vertical transmission of human immunodeficiency virus type 1: insights from studies of multiple pregnancies. Acta Pediatr, 1997, Suppl 421: 56-59.

236. Lewis P et al. Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis, 1998, 177(1): 34-39.

237. Dunn DT et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet, 1992, 340: 585-588.

238. Gray GE, McIntyre JA, Lyons SF. The effect of breastfeeding on vertical transmission of HIV-1 in Soweto, South Africa. XI International Conference on AIDS, Vancouver, 1997, Abstract ThC415.

239. Van de Perre P et al. Postnatal transmission of human immunodeficiency virus type 1 from mother to child: a prospective study in Kigali, Rwanda. N Engl J Med, 1991, 325: 585-588.

240. Kambarami RA, Kowo H. The prevalence of nipple disease among breast feeding mothers of HIV seropositive infants. Cent Afr J Med, 1997, 43(1): 20-22.

241. Bulterys M et al. HIV-1 seroconversion after 20 months of age in a cohort of breastfed children born to HIV-1 infected women in Rwanda. AIDS, 1995, 9(1): 93-94.

242. Ekpini ER et al. Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire. Lancet, 1997, 349: 1054-1059.

243. Newell ML, Peckham C. Vertical transmission of HIV infection. Acta Paediatr, 1994, Suppl 400: 43-45.

244. Newell ML. Vertical transmission of HIV-1: risks and prevention. J Hosp Infect, 1995, 30(Supp l): 191-196.

245. Kuhn L, Stein Z. Mother to infant HIV transmission. Paediatr Perinat Epidemiol, 1995, 9(1): 1-29.

246. Reducing women’s vulnerability to HIV infection. Geneva, Joint United Nations Programme on HIV/AIDS, 1997: 1-6.

247. HIV and infant feeding. Geneva, Joint United Nations Programme on HIV/AIDS, 1997: 1‑ 2.

248. Kline A, Strickler J, Kempf J. Factors associated with pregnancy and pregnancy resolution in HIV seropositive women. Soc Sci Med, 1995, 40(11): 1539-1547.

249. Thackway SV et al. Fertility and reproductive choice in women with HIV-1 infection. AIDS, 1997, 11: 663-667.

250. McIntyre JA. Transmission of HIV from mother to child: strategies for prevention. Maternal & Child Health, 1996, 21(5): 116-118.

251. Shaffer N et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet, 1999, 353: 773-780.

252. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS, 1997, 11(Suppl B): S79-S87.

253. Gray GE. Antiretrovirals and their role in preventing mother-to-child transmission of HIV-1 infection. In: Van Praag E, Fernyak S, Katz AM (eds.) The implications of antiretroviral treatments. Informal Consultation April 1997, Geneva, World Health Organization, 1997 (WHO/ASD/97.2).

254. Brocklehurst P. Interventions for reducing mother‑ to‑ child transmission of HIV infection (Cochrane Review). In: The Cochrane Library. Oxford: Update Software.

255. Connor EM et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med, 1994, 331(18): 1173-1180.

256. Sperling RS et al. Maternal, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med, 1996, 335(22): 1621-1629.

257. Wade NA et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med, 1998, 339: 1409-14.

258. McIntosh K. Short (and shorter) courses of zidovudine. N Engl J Med, 1998, 339: 1487-1468.

259. Culnane M et al for the Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Lack of long‑ term effects of in utero exposure to zidovudine among uninfected children born to HIV‑ infected women. JAMA, 1999, 281(2): 151‑ 157.

260. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR, 1994, 43: RR-11.

261. Simonds RJ, Rogers M. Preventing perinatal HIV infection: how far have we come? JAMA, 1996, 275: 1514-1515.

262. Gibb DM et al. Uptake of interventions to reduce mother-to-child transmission of HIV in the United Kingdom and Ireland. AIDS, 1997, 11: F53-F58.

263. Landers DV, Sweet RL. Reducing mother-to-infant transmission of HIV - the door remains open. N Engl J Med, 1996, 334: 1664-1665.

264. Van de Perre P et al. Zidovudine and breast-feeding. AIDS Patient Care and STDs, 1997, 11(1): 4-5.

265. Mayaux MJ et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr, 1997, 131(6): 857-862.

266. Fiscus SA et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA, 1996, 275(19): 1483-1488.

267. Wiznia A. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA, 1996, 275: 1504-1506.

268. Dabis F et al. Zidovudine to decrease mother-to-child transmission of HIV-1: is it good for developing countries. AIDS, 1995, 9(2): 204-206.

269. Cartoux M et al. Acceptability of interventions to reduce mother-to-child transmission of HIV-1 in West Africa. J Acquir Immune Syndr Hum Retrovirol, 1996, 12: 290-292.

270. Meda N et al. The reduction of mother-child transmission of HIV infection in developing countries: potential intervention strategies, obstacles to implementation and perspectives. Santé, 1997, 7(2): 115-125.

271. Srinivas RV et al. Development of zidovudine-resistant HIV genotypes following postnatal prophylaxis in a perinatally infected infant. AIDS, 1996, 10(7): 795-796.

272. White A, Eldridge R, Andrews E and the Antiretroviral Pregnancy Registry Advisory Committee. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Pediatr, 1997, Suppl 421: 86-88.

273. Connor E et al and Protocol 076 and 219 study groups. Long term effect of ZDV exposure among uninfected infants born to HIV infected mothers in PACTG Protocol 076. 36th Interscience Conference on antimicrobial agents and chemotherapy, New Orleans, 1996, Abstract 111.

274. Ayers KM et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol, 1996, 32: 148-158.

275. Olivero OA et al. AZT is a genotoxic transplacental carcinogen in animal models. JAIDS, 1997, 14: A29 Abstract 52.

276. Mansergh G et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA, 1996, 276: 139-145.

277. Bueckert H. Costs and benefits of screening pregnant women for HIV (letter). Can Med Assoc J, 1996, 155(10): 1387.

278. Ecker JL. The cost-effectiveness of human immunodeficiency virus screening in pregnancy. Am J Obstet Gynecol, 1996, 174(2): 716-721.

279. Mauskopf J et al. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. JAMA, 1996, 276: 132-138.

280. Frenkel LM et al. Analysis of the maternal components of the AIDS Clinical Trial Group 076 zidovudine regimen in the prevention of mother-to infant transmission of human immunodeficiency virus type 1. J Infect Dis, 1997, 175: 971-974.

281. Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14: 145-152.

282. Dabis F et al for the DITRAME Study Group. 6‑ month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cô te d'Ivoire and Burkina Faso: a double‑ blind placebo‑ controlled multicentre trial. Lancet, 1999, 353: 786‑ 92.

283. Wiktor S et al. Short‑ course oral zidovudine for prevention of mother‑ to‑ child transmission of HIV‑ 1 in Abidjan, Cô te d'Ivoire: a randomised trial. Lancet, 1999, 353: 781‑ 785.

284. Glaxo cuts HIV drug cost for developing world. Nature, 1998, 392: 118.

285. Van Praag E, Fernyak S, Katz AM (eds.) The implications of antiretroviral treatments. Informal Consultation April 1997, Geneva, World Health Organization, 1997 (WHO/ASD/97.2).

286. Blanche et al. Zidovudine‑ lamivudine for prevention of mother to child HIV‑ 1 transmission. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago. Abstract 267, 1999.

287. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet, 1997, 349: 1086-1092.

288. Carpenter CCJ et al. Antiretroviral therapy for HIV infection in 1997. JAMA, 1997, 277: 1962-1969.

289. [1]. De Cock K. Guidelines for managing HIV infection (editorial). Br Med J, 1997, 315: 1-2.

290. Augenbaum M, Minkoff HL. Antiretroviral therapy in the pregnant woman. Obstet Gynecol Clin North Am, 1997, 24(4): 833-854.

291. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR, 1998, 47(Rr-2): 1-30.

292. Lambert IS. The prevention of maternal-fetal HIV-1 infection through passive antibody products (HIVIG) and active immunisation (AIDS vaccines). Pediatr AIDS HIV Infect Fetus Adolesc, 1995, 6: 300-302.

293. Stiehm R et al. for the Pediatric AIDS Clinical Trials Group Protocol 185 Team. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV‑ infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. JID, 1999, 179: 567‑ 575.

294. Fast P, Newell M, Mofenson P. Strategies for prevention of perinatal transmission of HIV infection. Report of a consensus workshop (II) Sienna Italy, June 3-6, 1993. J Acquir Immune Defic Syndr Hum Retrovirol, 1993, 8: 161-175.

295. Fawzi WW et al for the Tanzania Vitamin and HIV Infection Trial Team. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1 infected women in Tanzania. Lancet, 1998, 351: 1477-1478.

296. Moodley D, Bobat RA, Cousidis A, Coovadia HM. Caesarean section and vertical transmission of HIV-1. Lancet, 1994, 34: 338.

297. Read J. Mode of delivery and vertical transmission of HIV‑ 1: a meta analysis from fifteen prospective cohort studies (The International Perinatal HIV Group). 12th World AIDS Conference, Geneva, 28 June ‑ 3 July 1998, Abstract 23603.

298. Fowler MG, Mofenson L. Progress in the prevention of perinatal HIV-1. Acta Pediatr, 1997, Suppl 421: 97-103.

299. Burman LG et al. Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. Lancet, 1992, 340: 65-69.

300. Taha TE et al. The effect of cleansing the birth canal with antiseptic solution on maternal, and newborn morbidity and mortality in Malawi: clinical trial. Br Med J, 1997, 315: 216-219.

301. Hofmeyr GJ, McIntyre JA. Preventing perinatal infections (editorial). Br Med J, 1997, 315(7102): 199-200.

302. Tess BH et al. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. AIDS, 1998, 12(5): 513-520.

303. Bobat R et al. Breastfeeding by HIV-1 infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS, 1997, 11(13): 1627-1633.

304. Kreiss J. Breastfeeding and vertical transmission of HIV-1. Acta Pediatr 1997, Suppl 421: 113-117.

305. Kuhn L, Stein Z. Infant survival, HIV infection and feeding alternatives in less-developed countries. Am J Public Health, 1997, 87(6): 926-931.

306. Zimmer P, Garza C. Maternal considerations in formulating HIV-related breast-feeding recommendations (editorial). Am J Public Health, 1997, 87(6): 904-906.

307. The Italian Register for HIV Infection in Children. Human immunodeficiency virus type 1 infection and breast milk. Acta Paediatr, 1994, Suppl 400: 51-58.

308. Kennedy KA, Visness CM, Rogan WJ. Breastfeeding and AIDS: a health policy analysis. AIDS & Public Policy J, 1992, Spring: 18-27.

309. Nicoll A et al. Infant feeding policy and practice in the presence of HIV-1 infection. AIDS, 1995, 9: 107-109.

310. Brookmeyer R et al. Estimating the rate of occurrence of new HIV infections using serial prevalence surveys: the epidemic in India. AIDS, 1996, 19(8): 924-925.

311. Recent HIV seroprevalence levels by country. Washington, DC, United States Bureau of the Censuses, Health Studies Branch, 1993.

312. Sherr L. HIV testing in pregnancy. In: Squire C (ed.) Women and AIDS: psychological perspectives. London, Sage Publications, 1993: 42-68.

313. Meadows J, Catalan J. Comment on " Is HIV testing in antenatal clinics worthwhile? Can we afford it? " AIDS Care, 1995, 7(2): 143-145.

314. Saba J. Identification of HIV infection in pregnancy: another era. Acta Pediatr, 1997, Suppl 421: 65-66.

315. Minkoff H, Willoughby A. The future of prenatal HIV testing. Acta Pediatr, 1997, Suppl 421: 72-77.

316. American Medical Association. Provisional Committee on Pediatric AIDS Perinatal Human Immunodeficiency Virus Testing. Pediatrics, 1995, 95(2): 303-307.

317. Grady GF. HIV mass screening of infants and mothers: historical, technical and practical issues. Acta Paediatr Suppl, 1994, 40: 39-42.

318. Brenner B. Testing for HIV in pregnancy: some ethical considerations. N Z Med J, 1996, 109(1032): 409-410.

319. Chrystie IL et al. Is HIV testing in antenatal clinics worthwhile? Can we afford it? AIDS Care, 1995, 7(2): 135-1142.

320. Phillips KA et al. HIV counseling and testing of pregnant women and women of childbearing age by primary care providers: self reported beliefs and practices. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14: 174-178.

321. Houshyar A. Screening pregnant women for HIV antibody: cost-benefit analysis. AIDS & Public Policy J, 1991, 6(2): 98-103.

322. Fischer CT. Prenatal and neonatal HIV testing (letter). JAMA, 1996, 275(5): 357.

323. The status and trends of the global HIV/AIDS pandemic. Satellite symposium, July 5-6 1996. Geneva, Joint United Nations Programme on HIV/AIDS, 1996.

324. Bergsjo P. African strategy. How to fight the human immunodeficiency virus. Acta Obstet Gynecol Scand, 1995, 74: 325-329.

325. Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for HIV of pregnant women. MMWR, 1995, 44: 1-15.

326. Department of Health. Guidelines for offering voluntary named HIV antibody testing to women receiving antenatal care. London, Department of Health, 1994.

327. Noone A, Goldberg D. Antenatal testing: what now? Br Med J, 1997, 314: 1429-1430.

328. Lewis R et al. The impact of initiating a human immunodeficiency virus screening program in an urban obstetric population. Am J Obstetr Gynecol, 1995, 173(4): 1329-1333.

329. Minkoff H, Willoughby A. Pediatric HIV disease, zidovudine in pregnancy and unblinding heelstick surveys. JAMA, 1995, 274(14): 1165-1168.

330. Macdonagh SE et al. Descriptive survey of antenatal HIV testing in London: policy, uptake and detection. Br Med J, 1996, 313: 532-533.

331. Phillips KA et al. HIV counselling and testing of pregnant women (letter). JAMA, 1996, 276(4): 283-284.

332. Centers for Disease Control and Prevention. HIV testing among women aged 18-44 years - United States 1991 and 1993. Morb Mortal Wkly Rep, 1996, 45(34): 733-737.

333. Rey D et al. Knowledge and behaviour of pregnant women towards HIV infection and screening. J Gynecol Obstet Biol Reprod (Paris), 1997, 26(1): 57-63.

334. Adu-Sarkodie Y. Why Abena is not having an HIV test. Br Med J (SA edition), 1996, 4: 725.

335. Rothenberg KH, Paskey SJ. The risk of domestic violence and women with HIV infection: implications for partner notification, public policy and the law. Am J Public Health, 1995, 85: 1569-1576.

336. Lester P et al. The consequences of a positive prenatal HIV antibody test for women. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 10: 341-349.

337. Temmerman M et al. The right not to know HIV-test results. Lancet, 1995, 345: 969-970.

338. Ladner J et al. A cohort study of factors associated with failure to return for HIV post test counselling in pregnant women: Kigali, Rwanda, 1992-1993. AIDS, 1996, 10: 69-75.

339. Sorin MD, Tesoriero JM, LaChance-McCullough ML. Correlates of acceptance of HIV testing and post-test counselling in the obstetrical setting. AIDS Educ Prev, 1996, 8(1): 71-85.

340. World Health Organization. The importance of simple/rapid assays in HIV testing: WHO recommendations. Weekly Epidemiological Record, October 1998.

341. World Health Organization. Revised recommendations for the selection and cure of HIV antibody tests. Weekly Epidemiological Record, 1997, 72: 81-83.

342. Wilkinson D et al. On site HIV testing in resource poor settings: is one rapid test enough? AIDS, 1997, 11: 377-381.

343. Kassler WJ et al. On-site, rapid HIV testing with same day results and counselling. AIDS, 1997, 11: 1045-1051.

344. Sherr L. Psychosocial aspects of providing care for women with HIV infection. In: Minkoff H, DeHovitz JA, Duerr A (eds.), HIV infection in women, New York, Raven Press, 1995: 107-123.

345. Sherr L. Pregnancy and childbirth. AIDS Care, 1997, 9: 69-77.

346. Levine C, Allen MH. Social interventions in the care of human immunodeficiency virus (HIV)-infected pregnant women. Semin Perinatol, 1995, 19(4): 232-329.

347. Provision of HIV/AIDS care in resource-strained settings. Geneva, World Health Organization, 1995 (WHO/GPA/TCO/HCS/95.14).

348. Kass NE. Policy, ethics and reproductive choice: pregnancy and childbearing among HIV infected women. Acta Paediatr Suppl, 1994, 400: 95-98.

349. De Vincenzi I et al and the SEROCO Study Group. Pregnancy and contraception in a French cohort of HIV-infected women. AIDS, 1997, 11: 333-338.

350. Johnstone FD et al. Women's knowledge of their HIV state: its effect on their decision whether to continue the pregnancy. Br Med J, 1990, 300: 23-24.

351. Selwyn P et al. Prospective study of human immunodeficiency virus infection and pregnancy outcome in intravenous drug users. JAMA, 1989, 261: 1289-1294.

352. Allen S et al. Pregnancy and contraception use among Rwandan women after HIV testing and counselling. Am J Public Health, 1993, 83(5): 705-710.

353. Lindsay MK et al. The impact of knowledge of Human Immunodeficiency Virus Serostatus on contraceptive choice and repeat pregnancy. Obstet Gynecol, 1995, 85: 675-679.

354. Amaro H. Reproductive choice in the age of AIDS: policy and counselling issues. In: Squire C (ed.) Women and AIDS: psychological perspectives. London, SAGE Publications, 1993: 21-41.

355. King R et al. A family planning intervention to reduce vertical transmission of HIV in Rwanda. AIDS, 1995, 9(Suppl 1): S45-S51.

356. Stephenson JM, Griffioen A and the study group for the Medical Research Council. Collaborative Study of Women with HIV. The effect of HIV diagnosis on reproductive experience. AIDS, 1996, 10: 1683-1687.

357. Allen S et al. Confidential HIV testing and condom promotion in Africa. JAMA, 1992, 268: 3338-3343.

358. Baker DA. Management of the female HIV-infected patient. AIDS Research and Human Retroviruses, 1994, 10: 935-938.

359. McIntyre JA. Management of HIV positive pregnant women. Cont Med Educ, 1996, 14(6): 781-788.

360. McIntyre JA. HIV/AIDS. In: Topics in Obstetrics & Gynaecology, Bassin J (ed.) Johannesburg, Julmar Communications, 1994: 72-77.

361. Silebi MI. Case management of the perinatal patient with HIV infection. AIDS Patient Care, 1995: 82-85.

362. Scaravelli G, Thorne C, Newell ML. The management of pregnancy and delivery in HIV-infected women in Europe. Euro J Obstet Gynecol, 1995, 62: 7-13.

363. Cooper ER et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use in pregnancy and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis, 1996, 174: 1207-1211.

364. Tuomala RE. Prevention of transmission Pharmaceutical and obstetric approaches. Obstet Gynecol Clin North Am, 1997, 24(4): 785-795.

365. Campbell ID, Williams G. AIDS management: an integrated approach. Strategies for Hope No 3. London, Actionaid, 1990.

366. Urassa EJN et al. The role of HIV infection in pregnancy wastage in Dar es Salaam, Tanzania. J Obstet Gynaecol Central Af, 1992, 10: 70-72.

367. Sukwa TY, Bakketeig L, Kanyama I, Samdal HH. Maternal Human Immunodeficiency Virus infection and pregnancy outcome. Cent Afr J Med, 1996, 42(8): 233-235.

368. Newell M-L et al. Immunological markers in HIV-infected pregnant women. AIDS, 1997 11(15): 1859-1865.

369. Lepage P et al. Perinatal transmission of HIV-1: lack of impact of maternal HIV infection on characteristics of live births and neonatal mortality in Kigali, Rwanda. AIDS, 1990, 5: 295-300.

370. Mwakagile D et al. High frequency of sexually transmitted diseases among pregnant women in Dar es Salaam, Tanzania: need for intervention. East Afr Med J, 1996, 73(10): 675-678.

371. Govender L et al. Bacterial vaginosis and associated infections in pregnancy. Int J Gynecol Obstet, 1996, 55(1): 23-28.

372. Semba R. Overview of the potential role of vitamin A in mother-to-child transmission of HIV-1. Acta Pediatr, 1997, Suppl 421: 107-112.

373. Semba RD et al. Maternal vitamin A deficiency and child growth failure during human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 14: 219-222.

374. Semba RD et al. Infant mortality and m